- All sections
- C - Chemistrymetallurgy
- C07K - Peptides
- C07K 16/46 - Hybrid immunoglobulins
Patent holdings for IPC class C07K 16/46
Total number of patents in this class: 7543
10-year publication summary
|
291
|
385
|
420
|
496
|
448
|
424
|
512
|
559
|
499
|
358
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Regeneron Pharmaceuticals, Inc. | 4364 |
242 |
| F. Hoffmann-La Roche AG | 7942 |
177 |
| Hoffmann-La Roche Inc. | 3495 |
172 |
| Chugai Seiyaku Kabushiki Kaisha | 1372 |
140 |
| Amgen Inc. | 4129 |
133 |
| Genentech, Inc. | 4005 |
112 |
| Xencor, Inc. | 393 |
105 |
| Janssen Biotech, Inc. | 1568 |
77 |
| The Regents of the University of California | 20172 |
72 |
| Zymeworks Inc. | 262 |
71 |
| Kymab Limited | 255 |
69 |
| Amgen Research (Munich) GmbH | 256 |
66 |
| Merus N.V. | 218 |
63 |
| Ablynx N.V. | 400 |
57 |
| Novartis AG | 10686 |
56 |
| Sanofi | 4109 |
56 |
| Bristol-myers Squibb Company | 4845 |
50 |
| Daiichi Sankyo Company, Limited | 1878 |
48 |
| MacroGenics, Inc. | 233 |
48 |
| Genmab A/S | 432 |
47 |
| Other owners | 5682 |